Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Moodys
Federal Trade Commission
Healthtrust
Deloitte
Colorcon
Cerilliant
Dow
Baxter

Generated: January 16, 2018

DrugPatentWatch Database Preview

FULYZAQ Drug Profile

« Back to Dashboard

When do Fulyzaq patents expire, and when can generic versions of Fulyzaq launch?

Fulyzaq is a drug marketed by Napo Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-one countries.

The generic ingredient in FULYZAQ is crofelemer. One supplier is listed for this compound. Additional details are available on the crofelemer profile page.
Summary for FULYZAQ
International Patents:38
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Drug Prices:see details
DailyMed Link:FULYZAQ at DailyMed
Drug patent expirations by year for FULYZAQ
Pharmacology for FULYZAQ
Drug ClassAntidiarrheal

US Patents and Regulatory Information for FULYZAQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Napo Pharms Inc FULYZAQ crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for FULYZAQ

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
US Army
Medtronic
Harvard Business School
Chinese Patent Office
US Department of Justice
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot